Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection
Verified January 2015 by Juan Macías, Andaluz Health Service
Spanish National Health System
Information provided by (Responsible Party)
Juan Macías, Andaluz Health Service
First received: February 5, 2012
Last updated: January 13, 2015
Last Verified: January 2015
History of Changes
Objectives: 1. Primary objective: To Evaluate the rate of sustained virological response
(SVR) of pegylated interferon alfa-2b (Peg-IFN) plus ribavirin (RBV) plus nitazoxanide (NTZ)
in patients coinfected by HIV and HCV genotype 4 (HCV-4), never treated before (naïve) and
with a treatment failure to a standard therapy with Peg-IFN plus RBV (experienced), and to
compare it with the rate of SVR of these patients with Peg-IFN plus RBV is a historical
cohort. 2. Secondary objectives: In naive, as well as in experienced patients: a) To evaluate
the virological activity at weeks 4 and 12 after starting the combination of Peg-IFN plus RBV
plus NTZ in HIV/HCV-4-coinfected patients. b) To analyze the safety of Peg-IFN plus RBV plus
NTZ in HIV/HCV-4-coinfected patients.
Design: Pilot clinical trial without control to evaluate efficacy and safety (phase II).
Patients: Individuals with HIV infection and with confirmed chronic HCV infection.
Treatment: NTZ 500 mg every 12 hours during 4 weeks, followed by NTZ 500 mg every 12 hours plus Peg-IFN plus weigh-adjusted RBV for 48 weeks. Total duration of therapy: 52 weeks.
Primary variable: The proportion of patients with HCV RNA ≤10 IU/ml 24 weeks after finishing the programmed length of treatment.
Secondary variables: 1. The frequency of individuals with HCV RNA ≤10 IU/ml 12 weeks after finishing the programmed length of treatment. 2. The proportion of patients with HCV RNA ≤10 IU/ml at 4 and 12 weeks after adding PegIFN plus RBV to NTZ. 3. The frequency of severe adverse events.
Drug : Nitazoxanide
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Phase II Clinical Trial to Evaluate the Antiviral Activity of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in Individuals With Chronic Hepatitis Due to HCV Genotype 4 and Coinfected by HIV|
Further study details as provided by Juan Macías, Andaluz Health Service:
Primary Outcome Measures
Sustained virological response
[ Time Frame: 24 weeks after finishing the scheduled treatment ]
The proportion of patients with HCV RNA ≤10 IU/ml 24 weeks after finishing the programmed length of treatment (52 weeks).
- Safety of Peg-interferon plus ribavirin plus nitazoxanide
[ Time Frame: Every 4 weeks until 28 weeks of treatment, then every 8 weeks until the end of treatment (52 weeks) ]
The proportion of patients with grade 3 or 4 adverse events according to the WHO classification.
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||February 2015|
|Estimated Primary Completion Date:||February 2015 (Final data collection date for primary outcome measure)|
Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
Main Objective To evaluate the SVR rate of treatment with Peg-IFN alfa-2b plus RBV and NTZ in
patients coinfected with HIV and HCV genotype 4, both never exposed to therapy against HCV or
who failed a previous treatment with Peg-IFN plus RBV, and to compare with the SVR rate
obtained in patients with Peg-IFN plus RBV in a historical cohort.
- : In naive, as well as in experienced patients:
- To evaluate the virological activity at weeks 4 and 12 after starting the combination of Peg-IFN plus RBV plus NTZ in HIV/HCV-4-coinfected patients.
- To analyze the safety of Peg-IFN plus RBV plus NTZ in HIV/HCV-4-coinfected patients.
Disease or disorder under study Coinfection with HIV and HCV genotype 4.
Drugs under study Nitazoxanide 500 mg every 12 hours for 4 weeks followed by nitazoxanide 500 mg every 12 hours plus pegylated interferon alfa-2b 1.5 mcg/kg/week and weight-adjusted ribavirin for 48 weeks.
Study Population and total number of subjects Patients infected with HIV-1 with chronic HCV genotype 4 who meet the selection criteria.
Number of patients included in the study: 45. Eligibility
|Ages Eligible for Study:||18 Years to 65 Years|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- HIV infection.
- Infection with HCV genotype 4.
- No prior treatment with any interferon or no response to a previous treatment with Peg-IFN plus RBV. The lack of response will include both nonresponders, and those who showed relapse.
- Stable antiretroviral therapy 24 weeks before starting the study drugs, with undetectable plasma HIV RNA during that period of time.
- Commitment to use two non-hormonal contraception during the study and up to 24 weeks after treatment.
- Acceptance to give written informed consent to participate in the trial.
- Antiretroviral therapy including didanosine, stavudine, zidovudine and abacavir.
- Decompensated cirrhosis.
- Presence of other significant liver diseases, including chronic hepatitis or acute hepatitis B, acute hepatitis hepatitis A, hemochromatosis or deficiency of alpha-1 antitrypsin.
- Pregnancy and lactation.
- Men planning pregnancy with their partners during the study and up to 24 weeks after treatment.
- Active or uncontrolled depression, other psychiatric illness, or disease during the previous year which may, in the investigator's opinion, prevent participation in the study.
- Previous suicide attempt.
- Active thyroid disease or poorly controlled with treatment.
- Previous autoimmune diseases such as inflammatory bowel disease, psoriasis serious, or rheumatoid arthritis, which may be exacerbated by interferon.
- Chemotherapy or immunomodulatory 24 weeks before starting the study.
- Serious illness, including cancer or unstable coronary disease, 24 weeks before starting the study.
- Any chronic disease which, in the opinion of the investigator, may prevent complete the study.
- Presence of acute or active opportunistic infections 48 weeks before starting the study.
- Evidence of hepatocellular carcinoma or alpha-fetoprotein levels ≥ 50 ng / ml, unless an imaging technique shows no evidence of liver tumor, all obtained 24 weeks before starting the study.
- Hemoglobinopathy or other conditions that may facilitate hemolysis.
- Solid organ or bone marrow transplant.
- Known hypersensitivity to any of the drugs under study.
- Active consumption of drugs or alcohol in the opinion of the investigator would interfere with participation in the study. The use of methadone or other opiate replacement therapy is not considered an exclusion criterion.
- Serious side effects from treatment with Peg-IFN plus RBV in patients with prior
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01529073
Locations Show More
|Seville, Spain, 41014|
Sponsors and CollaboratorsJuan Macías
Spanish National Health System
|Principal Investigator:||Juan Macías, MD, PhD||Infectious Diseases and Microbiology Unit. Hospital Universitario de Valme. Servicio Andaluz de Salud|
|Responsible Party:||Juan Macías, MD, PhD, Andaluz Health Service|
|ClinicalTrials.gov Identifier:||NCT01529073 History of Changes|
|Other Study ID Numbers:||NTZSPA001|
|Study First Received:||February 5, 2012|
|Last Updated:||January 13, 2015|
Keywords provided by Juan Macías, Andaluz Health Service:HIV
genotype 4 HCV
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on June 21, 2018
This information is provided by ClinicalTrials.gov.